Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The trial also demonstrated significant improvements across multiple secondary endpoints
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Recognition across subsidiaries and geographies highlights pharma major’s focus on inclusive culture, employee experience, and global workforce development
The last-mile healthcare delivery across 1,100 villages, with focus on maternal health, diagnostics, and chronic disease management
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
Subscribe To Our Newsletter & Stay Updated
